Literature DB >> 30293234

Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia.

Karen Morris1, Graeme Reid, Sally Spencer.   

Abstract

BACKGROUND: Schizophrenia is a severe mental health condition that is characterised by positive symptoms, such as hallucinations and delusions; negative symptoms, such as flattened affect, thought disorder (disrupted speech), and lack of motivation; and cognitive symptoms, such as problems with memory and attention. Schizophrenia can occur as an isolated episode, or as a recurring cycle of remission and relapse, and is associated with impairment in psychosocial and occupational functioning.Although antipsychotic drugs are the main treatment for people with schizophrenia, in most countries mental health services usually provide a range of add-on interventions, including occupational therapy. This is a complex intervention designed to support and enable continued participation in daily life through engagement in activities and occupations meaningful to the individual. Occupational therapists are professionals trained to deliver therapy where the emphasis is on improving occupational function and participation rather than treating symptoms, and uses a wide range of methods based on the needs of individuals. However, similar interventions may also be delivered by staff not trained as occupational therapists.
OBJECTIVES: To examine the effects of occupational therapy delivered by occupational therapists compared to occupational therapy delivered by any other person for people with schizophrenia. SEARCH
METHODS: We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers) on 4 November 2016 and 26 July 2018. SELECTION CRITERIA: All randomised controlled trials evaluating the functional or clinical outcomes of occupational therapy, or both, for people with schizophrenia delivered by occupational therapists compared with occupational therapy for people with schizophrenia delivered by anyone other than occupational therapists. DATA COLLECTION AND ANALYSIS: Review authors independently inspected citations, selected studies, extracted data, and appraised study quality. MAIN
RESULTS: The search yielded 1633 records. Of these, we retrieved 17 full-text reports (14 studies) for further scrutiny, which we subsequently excluded as they did not meet our inclusion criteria. AUTHORS'
CONCLUSIONS: Currently there are no randomised controlled trials comparing delivery of occupational therapy for people diagnosed with schizophrenia by occupational therapists with delivery of similar interventions by anyone other than occupational therapists. Research studies employing methodologically robust trial designs are needed to establish whether or not there are better outcomes for people with a diagnosis of schizophrenia with occupational therapy that is delivered by trained occupational therapists.

Entities:  

Mesh:

Year:  2018        PMID: 30293234      PMCID: PMC6516954          DOI: 10.1002/14651858.CD012398.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  42 in total

1.  Clinical implications of Brief Psychiatric Rating Scale scores.

Authors:  Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf Engel
Journal:  Br J Psychiatry       Date:  2005-10       Impact factor: 9.319

2.  Imputing missing standard deviations in meta-analyses can provide accurate results.

Authors:  Toshi A Furukawa; Corrado Barbui; Andrea Cipriani; Paolo Brambilla; Norio Watanabe
Journal:  J Clin Epidemiol       Date:  2006-01       Impact factor: 6.437

Review 3.  Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology.

Authors:  Andrew C Leon; Craig H Mallinckrodt; Christy Chuang-Stein; Donald G Archibald; Graeme E Archer; Kevin Chartier
Journal:  Biol Psychiatry       Date:  2006-02-28       Impact factor: 13.382

Review 4.  Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials.

Authors:  Jane L Hutton
Journal:  Br J Haematol       Date:  2009-04-27       Impact factor: 6.998

Review 5.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

6.  A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia.

Authors:  Mario Fioravanti; Olimpia Carlone; Barbara Vitale; Maria Elena Cinti; Linda Clare
Journal:  Neuropsychol Rev       Date:  2005-06       Impact factor: 7.444

Review 7.  Schizophrenia.

Authors:  W T Carpenter; R W Buchanan
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

8.  [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].

Authors:  J P Boissel; M Cucherat; W Li; G Chatellier; F Gueyffier; M Buyse; F Boutitie; P Nony; M Haugh; G Mignot
Journal:  Therapie       Date:  1999 Jul Aug       Impact factor: 2.070

9.  Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia.

Authors:  M Marshall; A Lockwood; C Bradley; C Adams; C Joy; M Fenton
Journal:  Br J Psychiatry       Date:  2000-03       Impact factor: 9.319

Review 10.  Schizophrenia: a concise overview of incidence, prevalence, and mortality.

Authors:  John McGrath; Sukanta Saha; David Chant; Joy Welham
Journal:  Epidemiol Rev       Date:  2008-05-14       Impact factor: 6.222

View more
  1 in total

1.  Individual placement and support and employment in personality disorders: a registry based cohort study.

Authors:  T T Juurlink; F Lamers; H J F van Marle; W Zwinkels; M A Spijkerman; A T F Beekman; J R Anema
Journal:  BMC Psychiatry       Date:  2022-03-17       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.